Big Generic Drug Deal for Lannett

The month of September got off to a busy start, with more than 32 acquisitions announced in just the first week. The biggest deal, by disclosed price, was Lannett Company’s (NYSE: LCI) $1.23 billion bid for Kremers Urban Pharmaceuticals, a subsidiary of UCB S.A. (Euronext: UCB). The deal adds near-term growth potential for LCI, with 11 product applications pending at the FDA, five of which include Paragraph IV certifications. Lannett believes the acquisition will be accretive to adjusted EPS in fiscal 2016 in the mid- to high-single digits and 20% to 25% in fiscal 2017. Lannett expects to receive a significant tax benefit as a result of 338(h)(10) election with a value in excess of... Read More »